JAC Advance Access originally published online on February 4, 2005
Journal of Antimicrobial Chemotherapy 2005 55(3):312-316; doi:10.1093/jac/dki020
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
JAC vol.55 no.3 © The British Society for Antimicrobial Chemotherapy 2005; all rights reserved
Susceptibility profile of 29 clinical isolates of Rhodotorula spp. and literature review
Servicio de Micología, Centro Nacional de Microbiología, Instituto de Salud Carlos III, Ctra Majadahonda-Pozuelo Km 2, 28220 Majadahonda (Madrid), Spain
* Corresponding author. Tel: +34-91-5097961; Fax: +34-91-5097966; Email: mcuenca-estrella{at}isciii.es
Objective: In vitro susceptibility results of 29 clinical isolates of Rhodotorula spp. were analysed. In addition, the susceptibility profile of another 102 Rhodotorula isolates was reviewed.
Methods: The review included studies using antifungal susceptibility testing reference procedures or commercial methods exhibiting high correlation rates with reference procedures (Etest and Sensititre YeastOne). The 131 organisms analysed were 77 Rhodotorula mucilaginosa, 45 Rhodotorula glutinis and nine Rhodotorula spp.
Results and conclusions: Fluconazole, itraconazole and voriconazole were inactive in vitro against the majority of isolates. Amphotericin B and flucytosine exhibited good activity, being reasonable alternatives for empirical treatment. Ravuconazole was more active in vitro than other azole agents and it could be considered as an extended-spectrum triazole and maybe as a therapeutic alternative in treating infections caused by Rhodotorula species.
Keywords: Rhodotorula , susceptibility of emerging yeasts , fluconazole resistance , ravuconazole
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
|
|
A. Unal, A.N. Koc, M.H. Sipahioglu, F. Kavuncuoglu, B. Tokgoz, H.M. Buldu, O. Oymak, and C. Utas CAPD-Related Peritonitis Caused by Rhodotorula Mucilaginosa Perit. Dial. Int., September 1, 2009; 29(5): 581 - 582. [Full Text] [PDF] |
||||
![]() |
M. A. Pfaller, D. J. Diekema, D. L. Gibbs, V. A. Newell, H. Bijie, D. Dzierzanowska, N. N. Klimko, V. Letscher-Bru, M. Lisalova, K. Muehlethaler, et al. Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: 10.5-Year Analysis of Susceptibilities of Noncandidal Yeast Species to Fluconazole and Voriconazole Determined by CLSI Standardized Disk Diffusion Testing J. Clin. Microbiol., January 1, 2009; 47(1): 117 - 123. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Savini, F. Sozio, C. Catavitello, M. Talia, A. Manna, F. Febbo, A. Balbinot, G. Di Bonaventura, R. Piccolomini, G. Parruti, et al. Femoral Prosthesis Infection by Rhodotorula mucilaginosa J. Clin. Microbiol., October 1, 2008; 46(10): 3544 - 3545. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. N. Leaw, H. C. Chang, R. Barton, J.-P. Bouchara, and T. C. Chang Identification of Medically Important Candida and Non-Candida Yeast Species by an Oligonucleotide Array J. Clin. Microbiol., July 1, 2007; 45(7): 2220 - 2229. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Cuenca-Estrella, A. Gomez-Lopez, E. Mellado, G. Garcia-Effron, A. Monzon, and J. L. Rodriguez-Tudela In Vitro Activity of Ravuconazole against 923 Clinical Isolates of Nondermatophyte Filamentous Fungi Antimicrob. Agents Chemother., December 1, 2005; 49(12): 5136 - 5138. [Abstract] [Full Text] [PDF] |
||||

